Administer's net sales declined by 3.9% y/y, reflecting the challenging market conditions that have ...
Marimekko's third quarter revenue was in line with our estimates, yet profitability fell a tad short...
Q3 in line, limited news on design wins Reiterates target of 4-6 design wins in 2024 Ambition of 50-...
Potentiell vändpunkt Adtraction minskade omsättningen med 17,5 procent i det tredje kvartalet.
Redeye continues to be positive to Bredband2 following a Q3 report that beat our estimates by delive...
Coor rapporterade ett kvartal under Analysguidens förväntan.
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is recruiting the next patient cohort on the two ...
EBITA -1% vs FactSet consensus, +27% y-o-y Strong order book of EUR 382m (+108% y-o-y) Neutral est c...
Sales -12% and EBIT -2m vs. ABGSCe Weak performance in NW&FT, as market headwinds intensify Expect c...
14% EBIT beat on strong SC sales despite EE volume decrease Near-term headwinds from programme shut ...
Redeye raised its asset management assumptions following the strong report with CoinShares Physical ...
Redeye comments on G5’s Q3-results which saw somewhat softer topline than expected while gross margi...
Redeye updates its estimates and valuation following Freemelt’s Q3 report, which came in above our e...
NoHo Partners' Q3 2024 results missed Vara Research expectations on several items, but the guidance ...
Taaleri's Q3 2024 results were solid on an underlying basis and fairly in line with our estimates.
Redeye updates on Embracer ahead of Q2-results (due 14 November) where we expect another quarter wit...
Q3 numbers in line with estimates Guidance trimmed, but limited impact on estimates All share bid li...
Deliveries and sales in line, somewhat lower costs than expected Update on development studies and s...
Demand weak as expected, but improved by quarter-end Comps also ease in Q4, return to order growth l...
Redeye gives a brief comment on today’s news that the first patient has been included in the ELC-301...